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confirmed with a total of 5 deaths in each group, accounting
for a 24% mortality rate in the transapical approach versus
17% in the open surgery group.
Potential Limitation
Although our study was not randomized, we matched pa-
tients according to variables known to affect morbidity and
mortality after AVR. Regarding the comparability between
the 2 groups, it also seems important to mention that 6 pa-
tients from the surgical group were initially considered for
TAP–AVI, but eventually underwent PUS–AVR because
of an aortic annulus diameter larger than 25 mm. Another
limitation of our study is its retrospective nature. The study
was not a randomized trial, and some of the observed differ-
ences may thus be attributable to bias or unmeasured factors.
Furthermore, we are comparing a new procedure with an es-
tablished approach. Although this may underestimate the
true benefits of TAP–AVI once the initial learning curve
has been overcome, we believe that we have to share our
early experiences with other centers that are beginning to
pursuit this evolving approach worldwide. This way, sur-
geons will know what clinical results and problems they
may initially face with TAP–AVI as compared with their es-
tablished practice of AVR. Besides, even with growing in-
ternational experience, the initial learning curve of an
individual center cannot be completely eliminated.
In summary, current data suggest a faster postoperative re-
covery after TAP–AVI with early and late morbidity and
mortality comparable with those of PUS–AVR.
References
1. Melby SJ, Zierer A, Kaiser SP, Guthrie TJ, Keune JD, Schuessler RB, et al. Aortic
valve replacement in octogenarians: risk factors for early and late mortality. Ann
Thorac Surg. 2007;83:1651-6; discussion 1656-7.
2. Sundt T, Bailey MS, Moon MR, Mendeloff EN, Huddleston CB, et al. Quality of
life after aortic valve replacement at the age of>80 years. Circulation. 2000;
102(19 Suppl. 3):III70-4.
3. Roberts WC, Ko JM, Garner WL, Filardo G, Henry AC, Hebeler RF Jr, et al.
Valve structure and survival in octogenarians having aortic valve replacement
for aortic stenosis (þ/- aortic regurgitation) with versus without coronary artery by-
pass grafting at a single US medical center (1993 to 2005). Am J Cardiol. 2007;
100:489-95.
4. Bose AK, Aitchison JD, Dark JH. Aortic valve replacement in octogenarians.
J Cardiothorac Surg. 2007;2:33.
5. Urso S, Sadaba R, Greco E, Pulitani I, Alvarez L, Juaristi A, et al. One-hundred
aortic valve replacements in octogenarians: outcomes and risk factors for early
mortality. J Heart Valve Dis. 2007;16:139-44.
6. Kolh P, Kerzmann A, Honore C, Comte L, Limet R. Aortic valve surgery in oc-
togenarians: predictive factors for operative and long-term results. Eur J Cardio-
thorac Surg. 2007;31:600-6.
7. Alexander KP, Anstrom KJ, Muhlbaier LH, Grosswald RD, Smith PK, Jones RH,
et al. Outcomes of cardiac surgery in patients>or ¼ 80 years: results from the
National Cardiovascular Network. J Am Coll Cardiol. 2000;35:731-8.
8. Chang YS, Lin PJ, Chang CH, Chu JJ, Tan PP. ‘‘I’’ ministernotomy for aortic
valve replacement. Ann Thorac Surg. 1999;68:40-5.
9. Tabata M, Umakanthan R, Cohn LH, Bolman RM 3rd, Shekar PS, Chen FY, et al.
Early and late outcomes of 1000 minimally invasive aortic valve operations. Eur J
Cardiothorac Surg. 2008;33:537-41.
10. Cohn LH, Adams DH, Couper GS, Bichell DP. Minimally invasive aortic valve
replacement. Semin Thorac Cardiovasc Surg. 1997;9:331-6.
11. Cosgrove DM 3rd, Sabik JF. Minimally invasive approach for aortic valve oper-
ations. Ann Thorac Surg. 1996;62:596-7.
12. Boehm J, Libera P, Will A, Martinoff S, Wildhirt SM. Partial median ‘‘I’’ sternot-
omy: minimally invasive alternate approach for aortic valve replacement. Ann
Thorac Surg. 2007;84:1053-5.
13. Cribier A, Eltchaninoff H, Bash A, Borenstein N, Tron C, Bauer F, et al. Percu-
taneous transcatheter implantation of an aortic valve prosthesis for calcific aortic
stenosis: first human case description. Circulation. 2002;106:3006-8.
14. Cribier A, Eltchaninoff H, Tron C, Bauer F, Agatiello C, Sebagh L, et al. Early
experience with percutaneous transcatheter implantation of heart valve prosthesis
for the treatment of end-stage inoperable patients with calcific aortic stenosis.
J Am Coll Cardiol. 2004;43:698-703.
15. Zierer A,Wimmer-Greinecker G,Martens S,MoritzA, DossM. The transapical ap-
proach for aortic valve implantation. J Thorac Cardiovasc Surg. 2008;136:948-53.
16. Ye J, Cheung A, Lichtenstein SV, Carere RG, Thompson CR, Pasupati S, et al.
Transapical aortic valve implantation in humans. J Thorac Cardiovasc Surg.
2006;131:1194-6.
17. Ye J, Cheung A, Lichtenstein SV, Pasupati S, Carere RG, Thompson CR, et al.
Six-month outcome of transapical transcatheter aortic valve implantation in the
initial seven patients. Eur J Cardiothorac Surg. 2007;31:16-21.
18. Walther T, Simon P, Dewey T,Wimmer-Greinecker G, Falk V, Kasimir MT, et al.
Transapical minimally invasive aortic valve implantation: multicenter experience.
Circulation. 2007;116(11 Suppl):I240-5.
19. Walther T, Falk V, Borger MA, Dewey T, Wimmer-Greinecker G, Schuler G,
et al. Minimally invasive transapical beating heart aortic valve implantation—
proof of concept. Eur J Cardiothorac Surg. 2007;31:9-15.
20. Cribier A, Eltchaninoff H, Tron C, Bauer F, Agatiello C, Nercolini D, et al. Treat-
ment of calcific aortic stenosis with the percutaneous heart valve: mid-term fol-
low-up from the initial feasibility studies: the French experience. J Am Coll
Cardiol. 2006;47:1214-23.
21. Dewey TM, Walther T, Doss M, Brown D, Ryan WH, Svensson L, et al. Trans-
apical aortic valve implantation: an animal feasibility study. Ann Thorac Surg.
2006;82:110-6.
22. Aronson S, Fontes ML, Miao T, Mangano DT. Risk index for perioperative renal
dysfunction/failure: critical dependence on pulse pressure hypertension. Circula-
tion. 2007;115:733-42.
23. Roques F, Nashef SA, Michel P. Risk factors for early mortality after valve sur-
gery in Europe in the 1990s: lessons from the EuroSCORE pilot program. J Heart
Valve Dis. 2001;10:572-7; discussion 577-8.
24. Toumpoulis IK, Anagnostopoulos CE, DeRose JJ, Swistel DG. Does Euro-
SCORE predict length of stay and specific postoperative complications after cor-
onary artery bypass grafting? Int J Cardiol. 2005;105:19-25.
25. Toumpoulis IK, Anagnostopoulos CE, Toumpoulis SK, DeRose JJ Jr,
Swistel DK. EuroSCORE predicts long-term mortality after heart valve surgery.
Ann Thorac Surg. 2005;79:1902-8.
26. Michel P, Roques F, Nashef SA. Logistic or additive EuroSCORE for high-risk
patients? Eur J Cardiothorac Surg. 2003;23:684-7; discussion 687.
27. Sergeant P, de Worm E, Meyns B. Single centre, single domain validation of the
EuroSCORE on a consecutive sample of primary and repeat CABG. Eur J Car-
diothorac Surg. 2001;20:1176-82.
28. Collart F, Feier H, Kerbaul F, Mouly-Bandini A, Riberi A, Mesana TG, et al. Val-
vular surgery in octogenarians: operative risks factors, evaluation of Euroscore
and long term results. Eur J Cardiothorac Surg. 2005;27:276-80.
29. Collart F, Feier H, Kerbaul F, Mouly-Bandini A, Riberi A, Di Stephano E, et al.
Primary valvular surgery in octogenarians: perioperative outcome. J Heart Valve
Dis. 2005;14:238-42; discussion 242.
30. Grossi EA, Schwartz CF, Yu PJ, Jorde UP, Crooke GA, Grau JB, et al. High-risk
aortic valve replacement: are the outcomes as bad as predicted? Ann Thorac Surg.
2008;85:102-6; discussion 107.
The Journal of Thoracic and Car
Zierer et al Acquired Cardiovascular Disease
A
C
DDiscussion
Dr Eric Roselli (Cleveland, Ohio). I am also a co-investigator
for the percutaneous valve trial.
Congratulations on a commendable early experience with this
new transapical technology. For now, I believe the real advantage
of this approach is that it offers the ability to provide nonoperative
candidates a viable treatment option for symptomatic and fatal dis-
ease. Although the EuroSCOREs were similar, this scoring system,
like others, has been criticized for the inability to capture lessdiovascular Surgery c Volume 138, Number 5 1071
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Dquantifiable factors that make a patient high risk. Furthermore, you
could not have matched patients for technical expertise during that
initial learning curve phase, although you did a nice job of address-
ing that point. Were any of these 21 patients deemed to be in inop-
erable condition and therefore part of a different population from
the matched cohort, and were any symptomatic patients with severe
aortic stenosis treated medically during this time period? If so, how
did they do?
Dr Doss. Thank you very much for your comments. Of course,
matching these patients is difficult. As you have pointed out, the
transapical group included patients who were in somewhat inoper-
able condition. We had patients with porcelain aortas and we had
redo patients, which we did not have in the surgical group. There-
fore, this was a very sick and very challenging operative group of
patients.
Dr Roselli.Did you evaluate any medically treated patients dur-
ing this time period?
Dr Doss. No, we did not have a medical treatment arm. We did
have patients who were on the waiting list and died while waiting
for surgery, but we did not have a specific medical arm for these
patients.
Dr Roselli. I believe that this technology will become another
important tool in our armamentarium, especially for high-risk pa-
tients, but I worry that the attraction of this less invasive approach
may cloud our judgment in providing patients with a durable oper-
ation, especially if the delivery systems improve access and accu-
racy in deployment. You had 5 patients, I believe, who required
repeat balloon valvuloplasty and 1 patient in each of the 2 groups
who required late reoperation. Can you provide any further fol-
low?up data on echocardiographic evidence of aortic insufficiency
and describe how you monitored these patients afterward?
Dr Doss. As I said before, 4 patients had paravalvular leakages;
the leakages were not significant. We followed them up according
to the protocol, which was after 30 days, after 6 months, and after 1
year, and thereafter we monitored them yearly. Of those patients
who had paravalvular leakages, none of the patients actually
went on to have a hemolysis, and none of the patients required a re-
operation for hemodynamic compromise. Also, none of these in-
competencies increased the grading. Therefore, it was something1072 The Journal of Thoracic and Cardiovascular Surthat we also had to learn—that leaving paravalvular leakages that
are not significant can actually be tolerated by the patient. A sur-
geon would try to reoperate on these patients as soon as possible,
but in these procedures, these patients tended to do well even
though these paravalvular leakages were not treated.
Dr Lars Svensson (Cleveland, Ohio). It is interesting to see how
the group of high-risk patients has increased in Europe, and that
certainly has been our impression with our patients. We looked at
our first 92 patients who were referred for percutaneous valves: es-
sentially 20% underwent open surgery with no deaths, 20% re-
ceived percutaneous valves and did pretty well, and 20% just had
balloon valvuloplasty; another 40% died before the procedure, re-
fused, or were not suitable for any type of procedure.
Are you doing a lot of balloon valvuloplasty bridging for later
procedures?
Dr Doss. Actually, we did that in only 2 patients. Those were
patients with very bad left ventricular function, less than 20%.
Bridging was done in an attempt to let them improve and then be
available for a later transapical procedure.
Dr William Northrup III (Kennesaw, Ga). I have one simple
question in the context of Craig Miller’s provocative presidential
address. How many of your patients eventually ended up going
back to their own ZIP codes?
Dr Doss. I did not quite get the phrase.
Dr Svensson. How many of those patients went back to normal
reasonable lifestyles in their home village?
DrDoss. The big advantage of the transapical procedure is that if
you treat these very sick patients, you actually see that they do have
a much improved and better course in the hospital. The second
patient on whom we performed the transapical procedure was
a 92-year-old man with coronary artery disease. We stented his
coronary arteries, 1 month later we did the procedure, and the pa-
tient returned to the hospital with his wife 1 year later. He was liv-
ing at home and taking care of himself. Of course, he will not live
another 10 years, but the improvement in his quality of life was dra-
matic. It is dramatic with this type of procedure. The transapical
procedure is worth doing, not necessarily to improve their survival,
but definitely to improve their quality of life during the time that
they have left.gery c November 2009
